Biotech Values

[jellybean]

I am not arguing that MNTA's drug will remain off the formulary, and I really don't want to have an argument with you because we all know that you are always right.

This board has batted back and forth the MNTA issue ad nauseum and the question I haven't seen addressed (and it's possible that I missed the discussion because I haven't followed the story closely) is what % of Lovenox sales are hospital based and since generic drugs must be "reviewed" by the P&T committees, does the "review" give Sanofi the ability to restructure contracts thereby dropping the price to hospitals?